SCHEMBL614355

SCHEMBL614355

CCN(CC)C1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL383574 0.97 ADH1A (0.46)
Phosphine SCHEMBL27880054 0.94 ADH1A (0.44)
SCHEMBL28388990 0.94 ADH1A (0.50)
SCHEMBL611858 0.94 ADH1A (0.50)
SCHEMBL356022 0.94 ADH1A (0.50)
SCHEMBL23073672 0.94 ADH1A (0.50)
SCHEMBL613463 0.94 ADH1A (0.50)
SCHEMBL612572 0.94 ADH1A (0.50)
SCHEMBL150343 0.94 ADH1A (0.50)
Fluoride SCHEMBL9620456 0.91 ADH1A (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024025953-A2 THERAPEUTIC USES OF UROLITHIN DERIVATIVES VANDRIA SA (CH) 2024-02-01 WO disclosed
US-20210236442-A1 METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2021-08-05 US disclosed
US-20190070178-A1 METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2019-03-07 US disclosed
EP-2076558-B1 COMPOSITION COMPRISING NEOPENTASILANE AND METHOD OF PREPARING SAME DOW CORNING (US) 2018-04-18 EP disclosed
US-9745321-B2 Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2017-08-29 US disclosed
EP-2427425-B1 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS INC (US) 2017-03-08 EP disclosed
EP-2125745-B1 CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES SANOFI SA (FR) 2017-02-22 EP disclosed
US-20160214994-A1 FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) 2016-07-28 US disclosed
US-9315451-B2 Tetracycline compounds TETRAPHASE PHARMACEUTICALS, INC. (US) 2016-04-19 US disclosed
CN-102405224-B Comprise composition and the Synthesis and applications thereof of season amino-functional silicoorganic compound EVONIK DEGUSSA GMBH (DE) 2015-12-16 CN disclosed
US-8147789-B2 Composition comprising neopentasilane and method of preparing same DOW CORNING CORPORATION (US) 2012-04-03 US disclosed
EP-2421874-A1 COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF Evonik Degussa GmbH (DE) 2012-02-29 EP disclosed
US-20120037040-A1 COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF EVONIK DEGUSSA GMBH (DE) 2012-02-16 US disclosed
WO-2011062253-A1 NOVEL FUSED PYRIMIDINE DERIVATIVE 大日本住友製薬株式会社 (JP) 2011-05-26 WO disclosed
WO-2010129057-A2 TETRACYCLINE COMPOUNDS TETRAPHASE PHARMACEUTICALS, INC. (US) 2010-11-11 WO disclosed
WO-2010121873-A1 COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF EVONIK DEGUSSA GMBH (DE) 2010-10-28 WO disclosed
US-20100176338-A1 Composition Comprising Neopentasilane And Method Of Preparing Same NATA SEMICONDUCTOR MATERIALS CO., LTD. (CN) 2010-07-15 US disclosed
EP-2076558-A1 COMPOSITION COMPRISING NEOPENTASILANE AND METHOD OF PREPARING SAME Dow Corning Corporation (US) 2009-07-08 EP disclosed
WO-2008051328-A1 COMPOSITION COMPRISING NEOPENTASILANE AND METHOD OF PREPARING SAME DOW CORNING CORPORATION (US) 2008-05-02 WO disclosed
US-4390712-A Aqueous solution of cationic organosilicon compounds and process for the production of the solutions DEGUSSA AG (DE) 1983-06-28 US disclosed